Forest Submits Schizophrenia Drug with FDA

Forest Laboratories has filed a New Drug Application (NDA) in the USA for the antipsychotic Cariprazine. Cariprazine, which was discovered by Hungary’s Gedeon Richter and licensed to Forest in the USA and Canada, has been submitted for the treatment of both schizophrenia and manic or mixed episodes connected to bipolar I disorder.

Continue Reading

Almirall Start Phase III trials & Announce Collaboration with BioFocus

Spain’s Almirall yesterday announced that they have linked up with UK drug discovery firm BioFocus to find new hit compounds against key targets of interest to Almirall.  These compounds will be used to support projects targeted at the treatment of respiratory and inflammatory conditions. BioFocus, the service division of Belgium’s Galapagos, will apply their screening

Continue Reading